Skip to content

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04331470
Enrollment
30
Registered
2020-04-02
Start date
2020-04-04
Completion date
2020-05-20
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

New Corona virus (COVID-19) has made a horrible situation for all of the countries. This disease is not only a health problem but also economy, culture and the whole entity of the countries is under attack by the virus. This disease seems to affect the body in two different pathology pathways. From one side virus can decrease activity of immune system in the blood stream and whole body and from other side it can attack the respiratory cells. Tissue biopsy shows that immune cells penetrate into the Lung tissue and we have accumulation and over activity of Immune cells in the lung. This inflammation in respiratory tract probably is the major cause of Cytokine storm and release of TNF-α and IL-6 into the blood. It seems that by three strategy disease can be treated. 1- By using systemic immune simulators. 2- By using topical anti-inflammatory drug in the respiratory system (Steroids or NSAIDs) 3- By inhibition of replication of the virus in the attacked cells.

Detailed description

Looking at the pathology of this disease shows that COVID-19 virus binds to the Angiotensin converting enzyme II (ACE II) which is located on the surface of different cells in the body and specially on the cells of respiratory system. This enzyme is responsible to turn angiotensin II into angiotensin1-7. It is also turns angiotensin I into angiotensin 1-9. When ACEII would be blocked by virus level of angiotensin II will be increased and this enzyme along with vasoconstriction, makes cells to manufacture TNF α and IL-6 which are responsible for cytokine storm and Lymphopenia. Also presence of virus and virus shell on the surface of the infected cells make immune system to attack to the respiratory system hence effect of angiotensin II inside the cell causes fibrosis of the respiratory cells. This inflammation and tissue damage make Acute Respiratory Distress syndrome (ARDS) which is lethal for patients. There is a dilemma in treatment of this infection. From one side it doesn't make sense to decrease the immune response hence it will make the infection worse. And from other side stimulation of the immune response because of respiratory inflammation can expedite process of lethal ARDS. A new strategy for treatment of this disease which consists of local anti- inflammatory and systemic immune stimulant drugs can be considered as a reasonable strategy.As immunostimulator, Levamisole can increase Lymphocytes and empower the immunity of the body. This drug can also bind to Papaine Like Protease(PL-pro) of the shell of the virus which is necessary for virulence of COVID-19. It also can decrease level of TNF α and IL-6, and as a chemical adjutant can introduce the virus to the immune system. In addition to Levamisole, Formoterol+Budesonide inhaler can be used in this protocol. Budesonide is a steroid and can suppress the immune reaction locally in the respiratory system. Formoterol is β2 agonist and can open airways. It also can bind to PL-pro and can neutralize the virus according to the published articles.

Interventions

DRUGLevamisole Pill + Budesonide+Formoterol inhaler

Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours

DRUGLopinavir/Ritonavir + hydoxychloroquine

Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours

Sponsors

Fasa University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

All of the research team will be blind about the groups of study and position of patients in each group except of physician and main researcher. Files of patients which will be numbered using a random number table will be sent for analyzer of the study.Information about position of patients in the groups is masked from research team. Outcomes Assessor will receive the information of patients without any name in the file. Just when statistical analysis would be finished information of groups will be revealed.

Intervention model description

Study is two armed , double blind, parallel, randomized clinical trial.

Eligibility

Sex/Gender
ALL
Age
15 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Definitely positive COVID-19 patients

Exclusion criteria

Patients with acute respiratory problems including patients with: 1. Spo2\<60% 2. Severe respiratory distress 3. Heamodynamic instabilitty 4. Acid base disturbance 5. Severe Anemia Patients with severe hepatic diseases Patients with Nurvous system diseases

Design outcomes

Primary

MeasureTime frameDescription
Clear chest CT-scanbetween 3-7 daysChest Ct scan should be negative
PCR testbetween 3-7 daysPCR test should be negative

Secondary

MeasureTime frameDescription
Physical statues of patientBetween 3-7 daysPatient should relief from signs of disease

Countries

Iran

Contacts

Primary ContactSiamack Afazeli, Pharm.D
Dr.afazeli@gmail.com+989121392982
Backup ContactMojtaba Farjaam, MD
farjam.md@gmail.com+989177104789

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026